Immune thrombocytopenia and pregnancy : an exposed/nonexposed cohort study
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Blood - 141(2023), 1 vom: 05. Jan., Seite 11-21 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
137046-51-6 |
|---|
| Anmerkungen: |
Date Completed 09.01.2023 Date Revised 16.11.2023 published: Print CommentIn: Blood. 2023 Jan 5;141(1):3-4. - PMID 36602822 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2022017277 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345721551 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345721551 | ||
| 003 | DE-627 | ||
| 005 | 20231226025721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2022017277 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1152.xml |
| 035 | |a (DE-627)NLM345721551 | ||
| 035 | |a (NLM)36054922 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guillet, Stéphanie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune thrombocytopenia and pregnancy |b an exposed/nonexposed cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.01.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2023 Jan 5;141(1):3-4. - PMID 36602822 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a 7-(4'-(2-nitroimidazole-1-yl)butyl)theophylline |2 NLM | |
| 650 | 7 | |a 137046-51-6 |2 NLM | |
| 700 | 1 | |a Loustau, Valentine |e verfasserin |4 aut | |
| 700 | 1 | |a Boutin, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Zarour, Anissa |e verfasserin |4 aut | |
| 700 | 1 | |a Comont, Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Souchaud-Debouverie, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat Chalumeau, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Pan-Petesch, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Gobert, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Cheze, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Viallard, Jean Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Morin, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Sauvetre, Gaetan |e verfasserin |4 aut | |
| 700 | 1 | |a Cliquennois, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Royer, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Masseau, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Terriou, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Fieschi, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Lambotte, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Girault, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Lioger, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Audia, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Sacre, Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Lega, Jean Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Langlois, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Benachi, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Orvain, Corentin |e verfasserin |4 aut | |
| 700 | 1 | |a Devidas, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Gambier, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Ruivard, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Zarrouk, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Ebbo, Mikael |e verfasserin |4 aut | |
| 700 | 1 | |a Willems, Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Segaux, Lauriane |e verfasserin |4 aut | |
| 700 | 1 | |a Mahevas, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Michel, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Canoui-Poitrine, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Godeau, Bertrand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 141(2023), 1 vom: 05. Jan., Seite 11-21 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2023 |g number:1 |g day:05 |g month:01 |g pages:11-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2022017277 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2023 |e 1 |b 05 |c 01 |h 11-21 | ||